Engineered immunoglobulin heavy chain-light chain pairs and uses thereof

Patent metadata

Field	Value
Publication number	US-11286293-B2
Application number	US-201816122417-A
Country	US
Kind code	B2
Filing date	Sep 5, 2018
Priority date	Nov 28, 2012
Publication date	Mar 29, 2022
Grant date	Mar 29, 2022

Abstract

The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the CH1 and/or CL domains, one or more amino acid modifications in the VH and/or VL domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.

First claim

We claim:

1. An isolated antigen binding polypeptide construct comprising at least a first heterodimer and a second heterodimer,
the first heterodimer comprising a first immunoglobulin G (IgG) heavy chain polypeptide sequence (H1) and a first immunoglobulin light chain polypeptide sequence (L1), and binding to a first epitope; and the second heterodimer comprising a second immunoglobulin G (IgG) heavy chain polypeptide sequence (H2) and a second immunoglobulin light chain polypeptide sequence (L2), and binding to a second epitope,
wherein at least one of the H1 or L1 sequences of the first heterodimer is distinct from the corresponding H2 or L2 sequence of the second heterodimer, H1 and H2 each comprise a heavy chain variable domain (V H domain) and a heavy chain constant domain (C H1 domain), and L1 and L2 each comprise a light chain variable domain (V L domain) and a light chain constant domain (C L domain);
wherein H1 preferentially pairs with L1 as compared to L2 and H2 preferentially pairs with L2 as compared to L1;
wherein:
a) H1 comprises amino acid substitutions 145L and 179E, L1 comprises amino acid substitution 131K, H2 comprises amino acid substitutions 146G and 179K, and L2 comprises amino acid substitutions 124E, 160E and 180E;
b) H1 comprises amino acid substitutions 145T and 179E, L1 comprises amino acid substitution 131K, H2 comprises amino acid substitution 186R, and L2 comprises amino acid substitution 180E;
c) H1 comprises amino acid substitutions 139W, 145T, and 179E, L1 comprises amino acid substitutions 986A and 131K, H2 comprises amino acid substitution 186R, and L2 comprises amino acid substitutions 135W, 160E and 180E;
d) H1 comprises amino acid substitutions 37W, 145T and 179E, L1 comprises amino acid substitutions 98A and 131K, H2 comprises amino acid substitution 186R, and L2 comprises amino acid substitutions 98W, 160E and 180E;
e) H1 comprises amino acid substitutions 37W, 145T and 179E, L1 comprises amino acid substitutions 98A and 131K, and L2 comprises amino acid substitution 98W;
f) H1 comprises amino acid substitutions 145L and 179E, L1 comprises amino acid substitution 131K, H2 comprises amino acid substitution 186R, and L2 comprises amino acid substitutions 124E, 160E and 178D; or
g) H1 comprises amino acid substitutions 145L and 179E, and L1 comprises amino acid substitution 131K;
wherein when both L1 and L2 are co-expressed with at least one of H1 and H2, the pairing of H1-L1 to H1-L2 and the pairing of H2-L2 to H2-L1 is greater than the pairing of H1-L1 to H1-L2 and the pairing of H2-L2 to H2-L1 in the absence of the amino acid substitutions,
and wherein the numbering of amino acid residues is according to Kabat.

2. The construct of claim 1 , wherein H1, H2, L1 and L2 are co-expressed in a cell or a mammalian cell, or H1, H2, L1 and L2 are co-expressed in a cell-free expression system, or H1, H2, L1 and L2 are co-produced, or H1, H2, L1 and L2 are co-produced via a redox production system.

3. The construct of claim 2 , wherein the first immunoglobulin light chain polypeptide sequence and/or the second immunoglobulin light chain polypeptide sequence is a kappa light chain polypeptide.

4. The construct of claim 2 , wherein the construct further comprises an Fc comprising two heavy chain constant domain polypeptides, each comprising a C H3 sequence, wherein the heavy chain polypeptides are coupled, with or without one or more linkers, to the first heterodimer and the second heterodimer.

5. The construct of claim 4 , wherein the Fc is a human Fc, a human IgG1 Fc, a human IgA Fc, a human IgG Fc, a human IgD Fc, a human IgE Fc, a human IgM Fc, a human IgG2 Fc, a human IgG3 Fc, or a human IgG4 Fc.

6. The construct of claim 5 , wherein the Fc is a heterodimeric Fc.

7. The construct of claim 6 , wherein the Fc comprises one or more modifications in at least one of the C H3 sequences that promote the formation of a heterodimeric Fc with stability comparable to a wild-type homodimeric Fc.

8. The construct of claim 7 , wherein:
a) one of the C H3 sequences comprises the amino acid substitutions L351Y, F405A, Y407V and the other comprises the amino acid substitutions T366L, K392M, T394W;
b) one of the C H3 sequences comprises the amino acid substitutions L351Y, F405A, Y407V and the other comprises the amino acid substitutions T366L, K392L, T394W;
c) one of the C H3 sequences comprises the amino acid substitutions T350V, L351Y, F405A, Y407V and the other comprises the amino acid substitutions T350V, T366L, K392M, T394W;
d) one of the C H3 sequences comprises the amino acid substitutions T350V, L351Y, F405A, Y407V and the other comprises the amino acid substitutions T350V, T366L, K392L, T394W; or
e) one of the C H3 sequences comprises the amino acid substitutions T350V, L351Y, S400E, F405A, Y407V and the other comprises the amino acid substitutions T350V, T366L, N390R, K392M, T394W,

wherein the numbering of amino acid residues of the C H3 sequences is according to the EU numbering system.

9. The construct of claim 8 , wherein the Fc further comprises at least one C H2 sequence.

10. The construct of claim 9 , wherein the Fc comprises one or more modifications to promote selective binding of Fc-gamma receptors.

11. The construct of claim 4 , wherein the one or more linkers are one or more polypeptide linkers, comprising one or more antibody hinge regions or one or more IgG1 hinge regions.

12. The construct according to claim 1 , wherein the sequences of each of H1, H2, L1, and L2 are derived from human or humanized sequences.

13. The construct according to claim 1 , wherein the construct is multispecific or bispecific.

14. The construct according to claim 8 , wherein the construct is conjugated to a therapeutic agent or drug.

15. A pharmaceutical composition comprising the construct of claim 1 and a pharmaceutically acceptable carrier.

16. The pharmaceutical composition according to claim 15 , further comprising one or more substances selected from the group consisting of a buffer, an antioxidant, a low molecular weight molecule, a drug, a protein, an amino acid, a carbohydrate, a lipid, a chelating agent, a stabilizer, and an excipient.

17. An isolated polynucleotide or set of isolated polynucleotides comprising at least one sequence that encodes the construct according to claim 1 .

18. The isolated polynucleotide of claim 17 , wherein the polynucleotide or set of polynucleotides is cDNA.

19. A vector or set of vectors comprising the isolated polynucleotide or set of isolated polynucleotides according to claim 17 .

20. The vector or set of vectors according to claim 19 , which is selected from the group consisting of a plasmid, a multi-cistronic vector, a viral vector, a non-episomal mammalian vector, an expression vector, and a recombinant expression vector.

21. An isolated cell comprising the vector or set of vectors according to claim 19 .

22. The isolated cell according to claim 21 , wherein the cell is a hybridoma, a Chinese Hamster Ovary (CHO) cell, or a HEK293 cell.

23. A method of obtaining the construct according to claim 1 from a host cell culture, the method comprising the steps of:
(a) obtaining a host cell culture comprising at least one host cell comprising one or more nucleic acid sequences encoding the construct; and
(b) recovering the construct from the host cell culture.

24. The method of claim 23 , wherein the construct comprises an Fc comprising at le

Assignees

• Zymeworks Inc

Inventors

• Corper Adam Louis
• Urosev Dunja
• Tom-Yew Stacey A L
• Bleile Dustin Weyland Blue
• Spreter Von Kreudenstein Thomas
• Dixit Surjit
• Lario Paula Irene
• Sanches Mario

Classifications

• C07K16/468 Primary

  Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/31

  multispecific · CPC title

• C07K2317/55

  Fab or Fab' · CPC title